Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $12.43, but opened at $11.9150. Sysmex shares last traded at $11.85, with a volume of 103,093 shares changing hands.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Sysmex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Sysmex Price Performance

The stock’s 50-day moving average price is $10.82 and its 200-day moving average price is $9.50. The company has a market capitalization of $7.44 billion, a price-to-earnings ratio of 28.14 and a beta of 1.09. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. The business had revenue of $825.85 million during the quarter, compared to analyst estimates of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Equities research analysts anticipate that Sysmex Corporation ADR will post 0.38 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.